. Author manuscript; available in PMC: 2017 Jan 4.

Published in final edited form as: JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137

Table 3.

Summary of Survival and Disease Progression/Recurrence End Points

End Point^a	Event	No. of Patients	No. of Events	Event-Free Survival Rate (95% CI)
End Point^a	Event	No. of Patients	No. of Events	At 12 mo	At 18 mo
Overall survival
All patients	Death from any cause	22	14	0.77 (0.62–0.97)	0.55 (0.37–0.80)
Resected patients	Death from any cause	15	8	0.73 (0.54–1.00)	0.43 (0.21–0.86)
Progression–free survival
All patients	Progression during preoperative treatment, recurrence after surgery, or death from any cause	22	15	0.59 (0.42–0.84)	0.41 (0.25–0.68)
Resected patients	Progression during preoperative treatment, recurrence after surgery, or death from any cause	15	8	0.53 (0.33–0.86)	0.40 (0.19–0.84)
Freedom from distant recurrence
Resected patients	Distant recurrence after resection	15	4	0.67 (0.45–1.00)	0.67 (0.45–1.00)
Freedom from locoregional recurrence
Resected patients	Locoregional recurrence after resection	15	2	0.90 (0.73–1.00)	0.60 (0.26–1.00)

In this table, for analyses based on all treated patients (n = 22), the registration date was the start date of the time-to-event end points; for analyses based on resected patients only (n = 15), the surgery date was the start date of the time-to-event end points.